Interruption and Reversal of Direct Oral Anticoagulants in Preprocedural and Acute Settings

References

1. 1.↵
   1. Desai NR,
   2. Krumme AA,
   3. Schneeweiss S,
   4. et al

   . Patterns of initiation of oral anticoagulants in patients with atrial fibrillation-quality and cost implications. Am J Med 2014;127:1075–82.e1.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Lane DA,
   2. Lip GYH

   . Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126:860–5.

   OpenUrlFREE Full Text
3. 3.↵
   1. You JJ,
   2. Singer DE,
   3. Howard PA,
   4. et al

   . Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e531S–e575S.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Camm AJ,
   2. Kirchhof P,
   3. Lip GYH,
   4. et al

   . Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. January CT,
   2. Wann LS,
   3. Alpert JS,
   4. et al

   . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2014;64:2246–80.

   OpenUrlFREE Full Text
6. 6.↵
   1. Connolly SJ,
   2. Ezekowitz MD,
   3. Yusuf S,
   4. et al

   . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Patel MR,
   2. Mahaffey KW,
   3. Garg J,
   4. et al

   . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Connolly SJ,
   2. Eikelboom J,
   3. Joyner C,
   4. et al

   . Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Granger CB,
   2. Alexander JH,
   3. McMurray JJV,
   4. et al

   . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Ng KH,
    2. Shestakovska O,
    3. Connolly SJ,
    4. et al

    . Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing 2016;45:77–83.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Giugliano RP,
    2. Ruff CT,
    3. Braunwald E,
    4. et al

    . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Diener HC,
    2. Aisenberg J,
    3. Ansell J,
    4. et al

    . Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J 2017;38:852–9.

    OpenUrl
13. 13.↵
    1. Diener HC,
    2. Aisenberg J,
    3. Ansell J,
    4. et al

    . Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017;38:860–8.

    OpenUrl
14. 14.↵
    1. Urooj F,
    2. Kulkarni A,
    3. Stapleton D,
    4. Kaluski E

    . New oral anticoagulants in nonvalvular atrial fibrillation. Clin Cardiol 2016;39:739–46.

    OpenUrl
15. 15.↵
    1. Bauersachs R,
    2. Berkowitz SD,
    3. et al

    EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–510.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Büller HR,
    2. Prins MH,
    3. et al

    EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287–97.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Agnelli G,
    2. Buller HR,
    3. Cohen A,
    4. et al

    . Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799–808.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Büller HR,
    2. Décousus H,
    3. et al

    Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406–15.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Schulman S,
    2. Kearon C,
    3. Kakkar AK,
    4. et al

    . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342–52.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Gould MK,
    2. Garcia DA,
    3. Wren SM,
    4. et al

    . Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e227S–e277S.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Falck-Ytter Y,
    2. Francis CW,
    3. Johanson NA,
    4. et al

    . Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e278S–e325S.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Kahn SR,
    2. Lim W,
    3. Dunn AS,
    4. et al

    . Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e195S–e226S.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Gibson CM,
    2. Halaby R,
    3. Korjian S,
    4. et al

    . The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (venous thromboembolism) Prevention with Extended-Duration Betrixaban (APEX) trial. Am Heart J 2017;185:93–100.

    OpenUrl
24. 24.↵
    1. Senoo K,
    2. Lane D,
    3. Lip GYH

    . Stroke and bleeding risk in atrial fibrillation. Korean Circ J 2014;44:281–90.

    OpenUrl
25. 25.↵
    1. Apostolakis S,
    2. Lane DA,
    3. Guo Y,
    4. Buller H,
    5. Lip GYH

    . Performance of the HEMORR 2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial. J Am Coll Cardiol 2012;60:861–7.

    OpenUrlFREE Full Text
26. 26.↵
    1. Roldán V,
    2. Marín F,
    3. Fernández H,
    4. et al

    . Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest 2013;143:179–84.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Kearon C,
    2. Akl EA,
    3. Ornelas J,
    4. et al

    . Antithrombotic therapy for VTE disease. Chest 2016;149:315–52.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Van Es N,
    2. Coppens M,
    3. Schulman S,
    4. Middeldorp S,
    5. Büller HR

    . Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968–75.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Chai-Adisaksopha C,
    2. Crowther M,
    3. Isayama T,
    4. Lim W

    . The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014;124:2450–8.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Abraham NS,
    2. Singh S,
    3. Alexander GC,
    4. et al

    . Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Holster IL,
    2. Valkhoff VE,
    3. Kuipers EJ,
    4. Tjwa ETTL

    . New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013;145:105–12.e15.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Castellucci LA,
    2. Cameron C,
    3. Le Gal G,
    4. et al

    . Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 2014;312:1122–35.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. January CT,
    2. Wann LS,
    3. Alpert JS,
    4. et al

    . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of cardiology/American Heart Association task force on practice guidelines and the heart rhythm society. Circulation 2014;130:e199–e267.

    OpenUrlFREE Full Text
34. 34.↵
    1. Wang X,
    2. Tirucherai G,
    3. Marbury TC,
    4. et al

    . Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016;56:628–36.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Douketis JD,
    2. Berger PB,
    3. Dunn AS,
    4. et al

    . The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008;133:299S–339S.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    1. Kovacs RJ,
    2. Flaker GC,
    3. Saxonhouse SJ,
    4. et al

    . Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol 2015;65:1340–60.

    OpenUrlFREE Full Text
37. 37.↵
    1. Patel IJ,
    2. Davidson JC,
    3. Nikolic B,
    4. et al

    . Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2012;23:727–36.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Burnett AE,
    2. Mahan CE,
    3. Vazquez SR,
    4. Oertel LB,
    5. Garcia DA,
    6. Ansell J

    . Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;41:206–32.

    OpenUrl
39. 39.↵
    1. Gage BF,
    2. Yan Y,
    3. Milligan PE,
    4. et al

    . Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713–9.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. Grove EL,
    2. Hossain R,
    3. Storey RF

    . Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013;109:817–24.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Singer DE,
    2. Chang Y,
    3. Borowsky LH,
    4. et al

    . A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013;2:e000250.

    OpenUrlAbstract/FREE Full Text
42. 42.↵
    1. Douketis JD,
    2. Spyropoulos AC,
    3. Spencer FA,
    4. et al

    . Perioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e326S–e350S.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.↵
    1. Doherty JU,
    2. Gluckman TJ,
    3. Hucker WJ,
    4. et al

    . 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2017;69:871–98.

    OpenUrlFREE Full Text
44. 44.↵
    1. Stangier J,
    2. Rathgen K,
    3. Sthle H,
    4. Mazur D

    . Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259–68.

    OpenUrlCrossRefPubMedWeb of Science
45. 45.↵
    1. Schulman S,
    2. Carrier M,
    3. Lee AYY,
    4. et al

    . Perioperative management of dabigatran: a prospective cohort study. Circulation 2015;132:167–73.

    OpenUrlAbstract/FREE Full Text
46. 46.↵
    1. Van Ryn J,
    2. Stangier J,
    3. Haertter S,
    4. et al

    . Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116–27.

    OpenUrlCrossRefPubMedWeb of Science
47. 47.↵
    1. Spyropoulos AC,
    2. Douketis JD

    . How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120:2954–62.

    OpenUrlAbstract/FREE Full Text
48. 48.↵
    1. Narouze S,
    2. Benzon HT,
    3. Provenzano D,
    4. et al

    . Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (second edition): guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2018;43:225–262.

    OpenUrl
49. 49.↵
    1. Douketis JD,
    2. Spyropoulos AC,
    3. Kaatz S,
    4. et al

    . Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823–33.

    OpenUrlCrossRefPubMed
50. 50.↵
    1. Zalpour A,
    2. Oo TH

    . Update on edoxaban for the prevention and treatment of thromboembolism: clinical applications based on current evidence. Adv Hematol 2015;2015.
51. 51.↵
    1. Lane DA,
    2. Aguinaga L,
    3. Blomström-Lundqvist C,
    4. et al

    . Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoame. EP Eur 2015;17:1747–69.

    OpenUrl
52. 52.↵
    1. Aronis KN,
    2. Hylek EM

    . Who, when, and how to reverse non-vitamin K oral anticoagulants. J Thromb Thrombolysis 2016;41:253–72.

    OpenUrlCrossRefPubMed
53. 53.↵
    1. Wanek MR,
    2. Horn ET,
    3. Elapavaluru S,
    4. Baroody SC,
    5. Sokos G

    . Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012;46:e21.

    OpenUrlCrossRefPubMed
54. 54.↵
    1. Tomaselli G,
    2. Mahaffey K,
    3. Cuker A,
    4. et al

    . 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol 2017;70:3042–3067.

    OpenUrlFREE Full Text
55. 55.↵
    1. Weitz JI,
    2. Pollack CV

    . Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2015;114:1113–26.

    OpenUrlCrossRefPubMed
56. 56.↵
    1. Godier A,
    2. Miclot A,
    3. Le Bonniec B,
    4. et al

    . Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012;116:94–102.

    OpenUrlCrossRefPubMedWeb of Science
57. 57.↵
    1. Heidbuchel H,
    2. Verhamme P,
    3. Alings M,
    4. et al

    . Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–507.

    OpenUrlCrossRefPubMed
58. 58.↵
    1. Ruff CT,
    2. Giugliano RP,
    3. Antman EM

    . Management of bleeding with non–vitamin K antagonist oral anticoagulants in the era of specific reversal agents. Circulation 2016;134:248–61.

    OpenUrlAbstract/FREE Full Text
59. 59.↵
    1. Dentali F,
    2. Marchesi C,
    3. Pierfranceschi MG,
    4. et al

    . Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. Thromb Haemost 2011;106:429–38.

    OpenUrlCrossRefPubMed
60. 60.↵
    1. Ehrlich HJ,
    2. Henzl MJ,
    3. Gomperts ED

    . Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8:83–90.

    OpenUrlCrossRefPubMedWeb of Science
61. 61.↵
    1. van Ryn J,
    2. Litzenburger T,
    3. Gan G,
    4. Coble K,
    5. Schurer J

    . In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran. Blood 2012;120:3418.

    OpenUrl
62. 62.↵
    1. Glund S,
    2. Moschetti V,
    3. Norris S,
    4. et al

    . A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015;113:943–51.

    OpenUrlCrossRefPubMed
63. 63.↵
    1. Glund S,
    2. Stangier J,
    3. Schmohl M,
    4. et al

    . Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 2014;124:344–344.

    OpenUrlAbstract/FREE Full Text
64. 64.↵
    1. Pollack CV,
    2. Reilly PA,
    3. van Ryn J,
    4. et al

    . Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017;377:431–41.

    OpenUrl
65. 65.↵
    1. Siegal DM,
    2. Curnutte JT,
    3. Connolly SJ,
    4. et al

    . Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24.

    OpenUrlCrossRefPubMed
66. 66.↵
    1. Lu G,
    2. Deguzman FR,
    3. Hollenbach SJ,
    4. et al

    . A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19:446–51.

    OpenUrlCrossRefPubMed
67. 67.↵
    1. Crowther M,
    2. Lu G,
    3. Conley P,
    4. et al

    . Reversal of factor XA inhibitors-induced anticoagulation in healthy subjects by andexanet ALFA. Crit Care Med 2014;42:A1469.

    OpenUrl
68. 68.↵
    1. Vandana M,
    2. Michael K,
    3. Genmin L,
    4. et al

    . A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for fxa inhibitors. Blood 2013;122:3636.

    OpenUrl
69. 69.↵
    1. Crowther M,
    2. Kitt M,
    3. Lorenz T,
    4. et al

    . A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors: AS 20.1. J Thromb Haemost 2013;11:30.

    OpenUrl
70. 70.↵
    1. Laulicht B,
    2. Bakhru S,
    3. Jiang X,
    4. et al

    . Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Thromb Haemost 2013;11:75.

    OpenUrl
71. 71.↵
    1. Laulicht B,
    2. Bakhru S,
    3. Lee C,
    4. Baker C

    . Small molecule antidote for anticoagulants. Circulation 2012;126:10021.

    OpenUrl
72. 72.↵
    1. Ansell JE,
    2. Bakhru SH,
    3. Laulicht BE,
    4. et al

    . Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014;371:2141–2.

    OpenUrlCrossRefPubMedWeb of Science
73. 73.↵
    1. Kubitza D,
    2. Becka M,
    3. Mueck W,
    4. et al

    . Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703–12.

    OpenUrlCrossRefPubMed
74. 74.↵
    1. Parasrampuria DA,
    2. Marbury T,
    3. Matsushima N,
    4. et al

    . Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 2015;113:719–27.

    OpenUrlCrossRefPubMed
75. 75.↵
    1. Dias C,
    2. Moore KT,
    3. Murphy J,
    4. et al

    . Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 2016;43:229–36.

    OpenUrl
76. 76.↵
    1. Chang M,
    2. Yu Z,
    3. Shenker A,
    4. et al

    . Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016;56:637–45.

    OpenUrlCrossRefPubMed